July 2021 Bonus Mid-Year Edition, Volume 7 Issue 9

July 2021 Bonus Mid-Year Edition

Volume 7, Issue 9

This issue features conversations with ASH Clinical Research Training Institute graduates, highlights from the virtual ASCO and EHA annual meetings, and more.

Table of Contents

July 2021 Bonus Mid-Year Edition

Transforming Ideas into Research Reality

Friday, July 16th, 2021
Participants come to the ASH Clinical Research Training Institute with ideas and enthusiasm, and leave with new skills to conduct patient-oriented research. Just 20 years...

July 2021 Bonus Mid-Year Edition

WIB_icon

Gene Therapy Shows Durable Efficacy in Young Patients With ADA Severe Combined Immune Deficiency

Friday, July 16th, 2021
Recent results published in Blood suggest gene therapy could offer an alternative to transplant for young patients with adenosine deaminase (ADA) severe combined immune...

Idelalisib and Obinutuzumab Combination Shows Promise in Relapsed/Refractory Waldenström Macroglobulinemia

Friday, July 16th, 2021
A combination regimen consisting of idelalisib and obinutuzumab led to promising response and survival rates in patients with relapsed and refractory Waldenström macroglobulinemia (WM),...

Reduced R-CHOP Intensity Does Not Compromise Survival in Older Patients With DLBCL

Friday, July 16th, 2021
Research suggests higher dose intensity R-CHOP (rituximab, cyclophosphamide, doxorubicin hydro-chloride, vincristine sulfate, and prednisone) can improve survival in patients with diffuse large B-cell lymphoma...

Gay and Bisexual Men Now Eligible to Donate Blood in the U.K.

Friday, July 16th, 2021
The National Health Service (NHS) has announced that gay and bisexual men who have been in monogamous relationships for at least three months can...

Third Dose of COVID-19 Vaccine May Boost Protection for Transplant Recipients

Friday, July 16th, 2021
According to results from a small study published in Annals of Internal Medicine, an extra dose of COVID-19 vaccine may boost protection in patients who...

Avapritinib Approved for Advanced Systemic Mastocytosis

Friday, July 16th, 2021
The FDA has approved avapritinib for the treatment of adult patients with advanced systemic mastocytosis (SM), SM with an associated hematologic neoplasm, and mast...

JAMA Editor-in-Chief Resigns After Releasing Content Questioning Racism in Medicine

Friday, July 16th, 2021
Howard Bauchner, MD, has resigned from his role as editor-in-chief of the Journal of the American Medical Association (JAMA) following a controversial podcast episode...

Pegcetacoplan Approved for Paroxysmal Nocturnal Hemoglobinuria

Friday, July 16th, 2021
The U.S. Food and Drug Administration (FDA) has approved the targeted C3 inhibitor pegcetacoplan for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria...

July 2021 Bonus Mid-Year Edition

On location

Deep and Durable Responses Seen With CAR T-Cell Therapy for Pretreated Myeloma

Friday, July 16th, 2021
In preliminary efficacy results, treatment with a single low-dose infusion of ciltacabtagene autoleucel (cilta-cel) led to early, deep, and durable responses in patients with...
On location

Direct Oral Anticoagulants Versus LMWH in Preventing Recurrent VTE in Cancer

Friday, July 16th, 2021
At the 2021 ASCO Annual Meeting, two posters reported results from the CANVAS trial, which described the risk-benefit profiles of direct oral anticoagulants (DOACs)...
On location

Functional, Nutritional, and Social Status Predict Survival Outcomes in Older Patients With CLL

Friday, July 16th, 2021
Geriatric domains of functional status, social activity, and nutritional status were associated with overall survival (OS) and progression-free survival (PFS) in older adults with...
On location

First-in-Human Study Finds FF-10101-01 Has Clinical Activity in Relapsed/Refractory FLT3-Mutated AML

Friday, July 16th, 2021
For patients with relapsed and/or refractory FLT3-mutated acute myeloid leukemia (AML), treatment with the selective and irreversible FLT3 inhibitor FF-10101-01 had promising clinical activity....
On location

R-CHOP Versus R-EPOCH: No Difference in Survival for Patients With MYC-Rearranged, Double- or Triple-Hit...

Friday, July 16th, 2021
Overall survival (OS) outcomes were similar between patients with MYC-rearranged diffuse large B-cell lymphoma (DLBCL) and double-hit lymphoma (DHL)/triple-hit lymphoma (THL) who were treated...
On location

Investigators Identify Distinct Molecular Subgroups to Guide Treatment Decisions in AML

Friday, July 16th, 2021
Analyzing genetic data from more than 3,000 patients with acute myeloid leukemia (AML), researchers from Memorial Sloan Kettering Cancer Center identified 14 distinct molecular...
On location

Rusfertide Helps Patients With Polycythemia Vera Avoid Phlebotomy

Friday, July 16th, 2021
Patients with polycythemia vera (PV) who received rusfertide were able to avoid therapeutic phlebotomy for seven months, even among those with high-risk disease, according...
On location

Head-to-Head Trial Confirms Acalabrutinib’s Noninferiority to Ibrutinib in CLL

Friday, July 16th, 2021
At EHA2021 Virtual, researchers presented results from the first head-to-head trial of Bruton tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia (CLL), finding that...
On location

Evaluating Maintenance Therapy After Fixed-Duration Obinutuzumab Plus Venetoclax in CLL

Friday, July 16th, 2021
For patients with chronic lymphocytic leukemia (CLL) who are considered unfit for FCR chemotherapy (fludarabine, cyclophosphamide, rituximab), a fixed-duration regimen of venetoclax plus obinutuzumab...
On location

Edoxaban Likely Prevents VTE Recurrence in Patients With Lung Cancer, Despite High Rates of...

Friday, July 16th, 2021
Many clinicians who manage patients with advanced lung cancer have frequently observed high rates of venous thromboembolism (VTE), but neither the incidence of VTE...
On location

Can Participation in Cancer Clinical Trials Save Money?

Friday, July 16th, 2021
Patients with cancer who were treated as part of a clinical trial had lower costs of care than similar patients who were receiving routine...